Drug interactions
Docetaxel + Erdafitinib
Severity: Moderate
Docetaxel and Erdafitinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Erdafitinib inhibits P-glycoprotein, and docetaxel is a P-gp substrate, so docetaxel exposure may increase. This could raise myelosuppression and other toxicity.
What this interaction means in plain words
Docetaxel and Erdafitinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Docetaxel belongs to Oncology; Erdafitinib belongs to Oncology.
Why it happens
Erdafitinib inhibits P-gp efflux of docetaxel.
What to do
Monitor blood counts and toxicity during co-use. Take erdafitinib at least 6 hours before or after P-gp substrates where separation is feasible, and reduce docetaxel if toxicity appears.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Docetaxel and Erdafitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Docetaxel
Other interactions of Erdafitinib
Frequently asked questions
Can I take Docetaxel with Erdafitinib?
MediHelp rates the interaction as moderate. Docetaxel and Erdafitinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Erdafitinib inhibits P-glycoprotein, and docetaxel is a P-gp substrate, so docetaxel exposure may increase. This could raise myelosuppression and other toxicity.
How serious is the interaction between Docetaxel and Erdafitinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and toxicity during co-use. Take erdafitinib at least 6 hours before or after P-gp substrates where separation is feasible, and reduce docetaxel if toxicity appears.
What other medicines interact with Docetaxel?
MediHelp also lists interactions of Docetaxel with, for example, Adenovirus types 4 and 7 live, Atazanavir, Belatacept. The full list is on the Docetaxel page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
